US Stock MarketDetailed Quotes
LSB LakeShore Biopharma
- 2.245
- +0.085+3.94%
Trading Nov 4 12:20 ET
42.84MMarket Cap-394P/E (TTM)
2.440High2.170Low4.07KVolume2.070Open2.160Pre Close9.40KTurnover0.11%Turnover RatioLossP/E (Static)19.08MShares11.20052wk High0.52P/B8.08MFloat Cap2.03052wk Low--Dividend TTM3.60MShs Float263.493Historical High--Div YieldTTM12.50%Amplitude2.030Historical Low2.307Avg Price1Lot Size
LakeShore Biopharma Key Stats
Quarterly+Annual
YOY
| (FY)Mar 31, 2024 | (FY)Mar 31, 2023 | (FY)Mar 31, 2022 | (FY)Mar 31, 2021 | |
|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||
| Cash flow from continuing operating activities | -61.80%-295.23M | -5.14%-182.47M | 29.63%-173.55M | -246.61M |
| Net income from continuing operations | -197.96%-433.46M | -37.24%-145.48M | 44.74%-106M | ---191.83M |
| Operating gains losses | -20,715.19%-4.45M | -107.80%-21.36K | 1,001.39%273.98K | --24.88K |
| Depreciation and amortization | 14.98%42.19M | 17.76%36.69M | 11.64%31.15M | --27.91M |
| Deferred tax | -2,016.94%-21.73M | -77.04%1.13M | -71.71%4.94M | --17.45M |
| Other non cash items | 8.03%4.78M | 16.79%4.42M | 69.61%3.79M | --2.23M |
| Change In working capital | 50.63%-45.79M | 25.77%-92.75M | 33.08%-124.94M | ---186.68M |
| -Change in receivables | 108.41%13.9M | -139.32%-165.25M | 69.15%-69.05M | ---223.82M |
| -Change in inventory | -375.23%-86.26M | 79.71%-18.15M | -30.16%-89.46M | ---68.73M |
| -Change in prepaid assets | -158.82%-5.29M | -84.82%8.99M | -59.64%59.23M | --146.77M |
| -Change in payables and accrued expense | -56.23%40.56M | 536.95%92.66M | 45.11%-21.21M | ---38.63M |
| -Change in other current liabilities | -11.85%-5.09M | -19.86%-4.55M | -70.83%-3.8M | ---2.22M |
| -Change in other working capital | 44.06%-3.61M | -881.77%-6.45M | -1,382.67%-656.67K | ---44.29K |
| Cash from discontinued investing activities | ||||
| Operating cash flow | -61.80%-295.23M | -5.14%-182.47M | 29.63%-173.55M | ---246.61M |
| Investing cash flow | ||||
| Cash flow from continuing investing activities | 22.34%-44.25M | 80.94%-56.98M | -186.77%-298.92M | -104.24M |
| Net PPE purchase and sale | 16.02%-44.25M | 82.16%-52.69M | -183.30%-295.31M | ---104.24M |
| Net intangibles purchase and sale | --0 | -18.63%-4.29M | ---3.62M | --0 |
| Cash from discontinued investing activities | ||||
| Investing cash flow | 22.34%-44.25M | 80.94%-56.98M | -186.77%-298.92M | ---104.24M |
| Financing cash flow | ||||
| Cash flow from continuing financing activities | -35.34%205.26M | -12.92%317.45M | -50.69%364.56M | 739.26M |
| Net issuance payments of debt | -178.25%-78.93M | -72.33%100.88M | 4,315.43%364.56M | --8.26M |
| Net common stock issuance | --284.2M | --0 | --0 | --1.59M |
| Net preferred stock issuance | ---- | ---- | ---- | --729.41M |
| Net other financing activities | ---- | --216.57M | ---- | ---- |
| Cash from discontinued financing activities | ||||
| Financing cash flow | -35.34%205.26M | -12.92%317.45M | -50.69%364.56M | --739.26M |
| Net cash flow | ||||
| Beginning cash position | 36.63%370.37M | -30.58%271.07M | 18,942.60%390.46M | --2.05M |
| Current changes in cash | -272.08%-134.22M | 172.28%78M | -127.78%-107.91M | --388.41M |
| Effect of exchange rate changes | -51.18%10.4M | 285.60%21.3M | -429,159.95%-11.48M | ---2.67K |
| End cash Position | -33.43%246.55M | 36.63%370.37M | -30.58%271.07M | --390.46M |
| Free cash flow | -41.73%-339.48M | 49.31%-239.52M | -34.42%-472.48M | ---351.49M |
| Currency Unit | CNY | CNY | CNY | CNY |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data